Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

Abstract	Aim: Radiological criteria alone do not reflect the entire population benefitting from checkpoint inhibitor therapy (CIT). This study aimed to detect patterns to assess CIT efficacy in non-small-cell lung cancer (NSCLC) patients. Materials & methods: We evaluated clinical, radiological and laboratory parameters in a retrospective cohort of NSCLC patients treated with nivolumab. Results: A total of 51 patients were included in the analysis. Most single parameters failed to reflect treatment benefit. Three laboratory parameters (lactate dehydrogenase, C-reactive protein and the neutrophil/lymphocyte ratio) combined in a weighted score could predict benefit with a sensitivity of 92.3% and a hazard ratio of 0.31 (95% CI: 0.16-0.59) in an early phase of therapy. Sorting patients by score showed a 1-year survival of 36% in those predicted as not benefitting versus 68% in those predicted to benefit. Conclusion: A weighted score integrating common serum markers could help detect patients benefitting from checkpoint inhibitors during ongoing CIT.
Authors	Annett Schiwitza, Hans-Ulrich Schildhaus, Birgit Zwerger, Josef Rüschoff, Christian Reinhardt, Andreas Leha, Stefan Andreas, Achim Rittmeyer
Journal	Immunotherapy (Immunotherapy) Vol. 11 Issue 9 Pg. 769-782 (06 2019) ISSN: 1750-7448 [Electronic] England
PMID	31120392 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents, Immunological B7-H1 Antigen PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab C-Reactive Protein
Topics	Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological (adverse effects, therapeutic use) B7-H1 Antigen (antagonists & inhibitors, metabolism) C-Reactive Protein (analysis) Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism, pathology) Female Humans Lung Neoplasms (drug therapy, metabolism, pathology) Male Middle Aged Nivolumab (adverse effects, therapeutic use) Pneumonia (chemically induced) Programmed Cell Death 1 Receptor (antagonists & inhibitors, metabolism) Retrospective Studies Survival Analysis Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!